var data={"title":"Oxymetazoline (nasal): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxymetazoline (nasal): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390313?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxymetazoline-nasal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxymetazoline (nasal): Patient drug information&quot;</a> and <a href=\"topic.htm?path=oxymetazoline-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxymetazoline (nasal): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504215\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>12 Hour Nasal Relief Spray [OTC];</li>\n      <li>12 Hour Nasal Spray [OTC];</li>\n      <li>Afrin 12 Hour [OTC];</li>\n      <li>Afrin Extra Moisturizing [OTC] [DSC];</li>\n      <li>Afrin Menthol Spray [OTC];</li>\n      <li>Afrin Nasal Spray [OTC];</li>\n      <li>Afrin NoDrip Extra Moisture [OTC];</li>\n      <li>Afrin NoDrip Original [OTC];</li>\n      <li>Afrin NoDrip Sinus [OTC];</li>\n      <li>Afrin Sinus [OTC];</li>\n      <li>Dristan Spray [OTC];</li>\n      <li>Long Lasting Nasal Spray [OTC];</li>\n      <li>Mucinex Nasal Spray Full Force [OTC];</li>\n      <li>Mucinex Nasal Spray Moisture [OTC];</li>\n      <li>Mucinex Sinus-Max Full Force [OTC];</li>\n      <li>Mucinex Sinus-Max Moist Smart [OTC] [DSC];</li>\n      <li>Nasal Decongestant Spray [OTC];</li>\n      <li>Nasal Spray 12 Hour [OTC];</li>\n      <li>Nasal Spray Extra Moisturizing [OTC];</li>\n      <li>Nasal Spray Max Strength [OTC];</li>\n      <li>Neo-Synephrine 12 Hour Spray [OTC];</li>\n      <li>NRS Nasal Relief [OTC] [DSC];</li>\n      <li>QlearQuil [OTC];</li>\n      <li>Sinus Nasal Spray [OTC];</li>\n      <li>Vicks Sinex 12 Hour Decongest [OTC];</li>\n      <li>Vicks Sinex Moisturizing [OTC];</li>\n      <li>Vicks Sinex Severe Decongest [OTC];</li>\n      <li>Vicks Sinex [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504216\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Claritin Allergic Decongestant;</li>\n      <li>Dristan Long Lasting Nasal;</li>\n      <li>Drixoral Nasal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9507255\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Adrenergic Agonist Agent;</li>\n      <li>\n        Decongestant;</li>\n      <li>\n        Imidazoline Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504424\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nasal congestion:</b> Intranasal:  Instill 2 to 3 sprays into each nostril twice daily for &le;3 days (maximum dose: 2 doses/24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504423\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oxymetazoline-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxymetazoline (nasal): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b> Nasal congestion:</b> Intranasal: Children &ge;6 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504425\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49103783\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49103784\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504460\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 Hour Nasal Relief Spray: 0.05% (15 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 Hour Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 Hour Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride, benzyl alcohol, edetate disodium, polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin 12 Hour: 0.05% (30 mL) [contains benzalkonium chloride, disodium edta, polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin Extra Moisturizing: 0.05% (30 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin Menthol Spray: 0.05% (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin Nasal Spray: 0.05% (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin Nasal Spray: 0.05% (15 mL, 20 mL, 30 mL) [contains benzalkonium chloride, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin NoDrip Extra Moisture: 0.05% (15 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin NoDrip Original: 0.05% (15 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin NoDrip Sinus: 0.05% (15 mL) [contains benzalkonium chloride, menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin Sinus: 0.05% (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dristan Spray: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Long Lasting Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucinex Nasal Spray Full Force: 0.05% (22 mL) [contains benzalkonium chloride, disodium edta, menthol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucinex Nasal Spray Moisture: 0.05% (22 mL) [contains benzalkonium chloride, edetate disodium, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucinex Sinus-Max Full Force: 0.05% (22 mL) [contains benzalkonium chloride, edetate disodium, menthol, polysorbate 80, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucinex Sinus-Max Moist Smart: 0.05% (22 mL [DSC]) [contains benzalkonium chloride, disodium edta, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Decongestant Spray: 0.05% (15 mL, 30 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Decongestant Spray: 0.05% (15 mL, 30 mL) [contains benzalkonium chloride, edetate disodium, polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Spray 12 Hour: 0.05% (30 mL) [contains benzalkonium chloride, benzyl alcohol, edetate disodium, polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Spray Extra Moisturizing: 0.05% (30 mL) [contains benzalkonium chloride, benzyl alcohol, edetate disodium, polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nasal Spray Max Strength: 0.05% (30 mL) [gluten free; contains benzalkonium chloride, benzyl alcohol, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neo-Synephrine 12 Hour Spray: 0.05% (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NRS Nasal Relief: 0.05% (15 mL [DSC]) [contains benzalkonium chloride, benzyl alcohol, disodium edta, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QlearQuil: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sinus Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride, edetate disodium, menthol, polysorbate 80, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vicks Sinex: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate disodium, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vicks Sinex 12 Hour Decongest: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vicks Sinex Moisturizing: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate disodium, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vicks Sinex Severe Decongest: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate disodium, menthol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (30 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504218\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49103785\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For intranasal use only. Before using for the first time, prime the pump by firmly depressing the rim several times. Keep head upright and insert nozzle into nostril, depress rim firmly, and inhale deeply.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504219\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nasal congestion: </b>Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50932409\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Topical vasoconstriction in nasal procedures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504320\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxymetazoline may be confused with oxymetholone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin may be confused with aspirin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afrin (oxymetazoline) may be confused with Afrin (saline)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neo-Synephrine (oxymetazoline) may be confused with Neo-Synephrine (phenylephrine, nasal)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504406\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dry nose, nasal congestion (rebound; chronic use), nasal mucosa irritation (temporary), sneezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504221\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use for more than 3 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for ophthalmic sympathomimetics is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504222\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local nasal effects: Temporary discomfort such as burning, stinging, sneezing, or an increased nasal discharge may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rebound nasal congestion: Frequent or prolonged use may cause nasal congestion to recur or worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with hypertension or heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who had ingested even small amounts (eg, 1 to 2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication (OTC), do not exceed recommended dosages; use of this container by more than one person may spread infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299804\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504410\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9896&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12711040\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse fetal/neonatal events have been noted in case reports following large doses or extended use of oxymetazoline nasal spray in the first trimester of pregnancy (Baxi 1985; Holm 1985; Menezes 2016). Fetal blood flow was not found to be affected by a one-time dose of oxymetazoline in noncomplicated, third trimester pregnancies (Rayburn 1990). Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Short-term (&lt;3 days) use of intranasal oxymetazoline may be beneficial to some patients although its safety during pregnancy has not been studied (Wallace 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49944664\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">If a decongestant is needed, nasal preparations may be preferred over systemic agents in nursing women (Anderson 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504416\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9504418\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Within 10 minutes (Chua 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Up to 12 hours (Chua 1989)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322391\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Afrin Menthol Spray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 mL): $5.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Afrin Nasal Spray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 mL): $5.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Afrin NoDrip Original Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 mL): $6.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Afrin Sinus Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 mL): $5.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dristan Spray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 mL): $4.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mucinex Nasal Spray Full Force Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (22 mL): $8.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mucinex Nasal Spray Moisture Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (22 mL): $8.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mucinex Sinus-Max Full Force Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (22 mL): $8.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neo-Synephrine 12 Hour Spray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 mL): $4.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390235\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afrin (AE, BD, BG, CO, CR, DO, EG, GT, HK, HN, ID, LK, LV, NI, PA, PE, SG, SV, VE);</li>\n      <li>Alrin (IL);</li>\n      <li>Aturgyl (FR);</li>\n      <li>Confree (BD);</li>\n      <li>Congesta (BD);</li>\n      <li>Dan Zhong Di Be Ye (CN);</li>\n      <li>Dimetapp 12 Hour Decongestant Spray (AU, NZ);</li>\n      <li>Drixine (AU, KR, NZ, PH);</li>\n      <li>Feenoze (TH);</li>\n      <li>Friresp (ES);</li>\n      <li>Iliadin (AE, CL, CR, DK, DO, GT, HK, HN, ID, NI, PA, PE, PH, SE, SV, TH, TR, ZA);</li>\n      <li>Lidil (UY);</li>\n      <li>Metzodin (TH);</li>\n      <li>Mexalon (VN);</li>\n      <li>Nafazol (CO);</li>\n      <li>Nasal Spray (PY);</li>\n      <li>Nasalox (BD);</li>\n      <li>Nasavin (PK);</li>\n      <li>Nasex (PT);</li>\n      <li>Nasin (VE);</li>\n      <li>Nasivin (AE, AT, BH, BR, CH, CZ, DE, HN, HR, JO, KW, LB, NL, PL, QA, RO, RU, SA);</li>\n      <li>Nasivion (IN);</li>\n      <li>Nasivon (LK);</li>\n      <li>Nasofree (PH);</li>\n      <li>Nazalonh (UA);</li>\n      <li>Nesivine (BE);</li>\n      <li>Nezeril (SE);</li>\n      <li>Numark (MT);</li>\n      <li>Operil (HR);</li>\n      <li>Operyl (UA);</li>\n      <li>Oxamet (CZ);</li>\n      <li>Oxazoline (AE, JO);</li>\n      <li>Oxinasal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oxymet (TH);</li>\n      <li>Respiben (KR);</li>\n      <li>Respibien (ES, PE);</li>\n      <li>Respir (ES);</li>\n      <li>Rhinoclir (IL);</li>\n      <li>Rinerge (PK);</li>\n      <li>Rinex (EC);</li>\n      <li>Rynex (BD);</li>\n      <li>Sinarest (LK);</li>\n      <li>Sinazol (ZW);</li>\n      <li>Sindecon (TW);</li>\n      <li>Sinex (LV);</li>\n      <li>Vicks Sinex (AU, BE, CH, FI, IE, MT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Afrin oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC: received January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO. Decongestants and milk production. <i>J Hum Lact</i>. 2000;16(4):294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/11155604/pubmed\" target=\"_blank\" id=\"11155604\">11155604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxi LV, Gindoff PR, Pregenzer GJ, et al, &quot;Fetal Heart Rate Changes Following Maternal Administration of a Nasal Decongestant,&quot; <i>Am J Obstet Gynecol</i>, 1985, 153(7):799-800.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/2416220 /pubmed\" target=\"_blank\" id=\"2416220 \">2416220 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. Biopharm Drug Dispos. 1989 Jan-Feb;10(1):1-14. Review. PubMed PMID: .<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/2647163/pubmed\" target=\"_blank\" id=\"2647163\">2647163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration. FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. U.S. Food and Drug Administration. October 25, 2012. Available at <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm</a>. Accessed September 5, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21271600\"></a>Higgins TS, Hwang PH, Kingdom TT, Orlandi RR, Stammberger H, Han JK. Systematic review of topical vasoconstrictors in endoscopic sinus surgery. <i>Laryngoscope</i>. 2011;121(2):422-432. doi: 10.1002/lary.21286.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/21271600/pubmed\" target=\"_blank\" id=\"21271600\">21271600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holm IA and Clarren SK, &quot;An Unusual Pattern of Malformation Associated With Gestational Exposure to Nasal Spray,&quot; <i>J Pediatr</i>, 1985, 106(5):860-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/3998934/pubmed\" target=\"_blank\" id=\"3998934\">3998934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8182859\"></a>Johns ME, Richtsmeier WJ. Otolaryngology--head and neck surgery. <i>JAMA</i>. 1994;271(21):1698-1700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/8182859/pubmed\" target=\"_blank\" id=\"8182859\">8182859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menezes GA, Araujo J&uacute;nior E, Lopes J, Belmonte S, Tonni G<sup>4</sup>, Werner H. Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester. <i>J Obstet Gynaecol Res</i>. 2016;42(8):1016-1020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/27087030/pubmed\" target=\"_blank\" id=\"27087030\">27087030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rayburn WF, Anderson JC, Smith CV, et al, &quot;Uterine and Fetal Doppler Flow Changes From a Single Dose of a Long-Acting Intranasal Decongestant,&quot; <i>Obstet Gynecol</i>, 1990, 76(2):180-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/2196495/pubmed\" target=\"_blank\" id=\"2196495\">2196495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8233500\"></a>Tarver CP, Noorily AD, Sakai CS. A comparison of cocaine vs. lidocaine with oxymetazoline for use in nasal procedures. <i>Otolaryngol Head Neck Surg</i>. 1993;109(4):653-659. doi: 10.1177/019459989310900404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/8233500/pubmed\" target=\"_blank\" id=\"8233500\">8233500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vicks Sinex (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received August 31, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vicks Sinex Moisturizing (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received August 31, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vicks Sinex Severe (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received August 31, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. <i>J Allergy Clin Immunol. </i>2008;122(2)(suppl):S1-S84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxymetazoline-nasal-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9896 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9504215\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9504216\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9507255\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9504424\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9504423\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9504425\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F49103783\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F49103784\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9504460\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9504218\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49103785\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9504219\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50932409\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9504320\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9504406\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9504221\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9504222\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299804\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9504410\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12711040\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F49944664\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9504416\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9504418\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322391\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390235\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9896|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxymetazoline-nasal-patient-drug-information\" class=\"drug drug_patient\">Oxymetazoline (nasal): Patient drug information</a></li><li><a href=\"topic.htm?path=oxymetazoline-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">Oxymetazoline (nasal): Pediatric drug information</a></li></ul></div></div>","javascript":null}